News & Updates

In a subgroup analysis of the phase IV FIRST trial presented at ASH 2021, the oral iron chelator deferiprone was comparable to the infusion-administered deferoxamine in terms of efficacy and safety in iron-overloaded children receiving chronic transfusion therapy for sickle cell disease (SCD) and other anaemias.

While there are no differences in COVID-19-related outcomes in patients with inflammatory bowel disease (IBD) between those in remission vs those who are not, being on medications such as corticosteroids and aminosalicylates may put them at higher risk of hospitalization, suggest studies presented at AIBD 2021.

The choice of oral anticoagulant does not appear to influence the outcome in terms of preserving cognitive function in older patients with atrial fibrillation (AF), the GIRAF* study has shown.

Treatment with the anti-interleukin (IL)-12/-23 monoclonal antibody ustekinumab yields a high rate of clinical remission in patients with moderate-to-severe Crohn’s disease (CD) in the real-world setting, according to a study presented at AIBD 2021.

For patients undergoing direct acting antiviral (DAA) therapy for hepatitis C virus (HCV)/hepatitis B virus (HBV) dual infection, cotreatment with entecavir helps avert reactivation of HBV, as shown in a study.

Think twice before withdrawing HBV treatment. Not all patients can safely discontinue nucleos(t)ide analogue (NA) therapy as shown in the retrospective RETRACT-B study of patients from Europe, North America, and Asia.